0000899243-17-029263.txt : 20171219
0000899243-17-029263.hdr.sgml : 20171219
20171219204406
ACCESSION NUMBER: 0000899243-17-029263
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20171215
FILED AS OF DATE: 20171219
DATE AS OF CHANGE: 20171219
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Vivo Ventures Fund V, L.P.
CENTRAL INDEX KEY: 0001398937
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36593
FILM NUMBER: 171265548
BUSINESS ADDRESS:
STREET 1: 505 HAMILTON AVENUE, SUITE 200
CITY: PALO ALTO
STATE: CA
ZIP: 94301
BUSINESS PHONE: 650-688-0818
MAIL ADDRESS:
STREET 1: 505 HAMILTON AVENUE, SUITE 200
CITY: PALO ALTO
STATE: CA
ZIP: 94301
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Vivo Ventures V Affiliates Fund, L.P.
CENTRAL INDEX KEY: 0001398936
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36593
FILM NUMBER: 171265549
BUSINESS ADDRESS:
STREET 1: 575 HIGH STREET, SUITE 201
CITY: PALO ALTO
STATE: CA
ZIP: 94301
BUSINESS PHONE: 650-688-0818
MAIL ADDRESS:
STREET 1: 575 HIGH STREET, SUITE 201
CITY: PALO ALTO
STATE: CA
ZIP: 94301
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Vivo Ventures V, LLC
CENTRAL INDEX KEY: 0001399028
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36593
FILM NUMBER: 171265550
BUSINESS ADDRESS:
STREET 1: 505 HAMILTON AVENUE, SUITE 200
CITY: PALO ALTO
STATE: CA
ZIP: 94301
BUSINESS PHONE: 650-688-0818
MAIL ADDRESS:
STREET 1: 505 HAMILTON AVENUE, SUITE 200
CITY: PALO ALTO
STATE: CA
ZIP: 94301
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: SOLENO THERAPEUTICS INC
CENTRAL INDEX KEY: 0001484565
STANDARD INDUSTRIAL CLASSIFICATION: ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845]
IRS NUMBER: 770523891
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1235 RADIO ROAD
STREET 2: SUITE 110
CITY: REDWOOD CITY
STATE: CA
ZIP: 94065
BUSINESS PHONE: 650-213-8444
MAIL ADDRESS:
STREET 1: 1235 RADIO ROAD
STREET 2: SUITE 110
CITY: REDWOOD CITY
STATE: CA
ZIP: 94065
FORMER COMPANY:
FORMER CONFORMED NAME: Capnia, Inc.
DATE OF NAME CHANGE: 20100219
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2017-12-15
0
0001484565
SOLENO THERAPEUTICS INC
SLNO
0001399028
Vivo Ventures V, LLC
505 HAMILTON AVENUE, SUITE 207
PALO ALTO
CA
94301
0
0
1
0
0001398936
Vivo Ventures V Affiliates Fund, L.P.
505 HAMILTON AVENUE, SUITE 207
PALO ALTO
CA
94301
0
0
1
0
0001398937
Vivo Ventures Fund V, L.P.
505 HAMILTON AVENUE, SUITE 207
PALO ALTO
CA
94301
0
0
1
0
Common Stock
2017-12-15
4
P
0
1072888
1.8425
A
3888137
I
See footnote
Common Stock
2017-12-15
4
P
0
12592
1.8425
A
45667
I
See footnote
Common Stock Warrant (Right to Buy)
2.00
2017-12-15
4
P
0
793937
A
2017-12-15
Common Stock
793937
793937
I
See footnote
Common Stock Warrant (Right to Buy)
2.00
2017-12-15
4
P
0
9318
A
2017-12-15
Common Stock
9318
9318
I
See footnote
The securities are held directly by Vivo Ventures Fund V. L.P. ("Vivo Ventures Fund V"). The Reporting Person is the sole general partner of Vivo Ventures Fund V, and may be deemed to beneficially own such securities. The Reporting Person holds voting and dispositive power with respect to the securities held by Vivo Ventures Fund V. Edgar Engleman, Albert Cha and Frank Kung are members of the Reporting Person and disclaim beneficial ownership of the securities held by Vivo Ventures Fund V, except to the extent of any pecuniary interest therein.
The securities are held directly by Vivo Ventures V Affiliates Fund L.P. ("Vivo Ventures V Affiliates Fund"). The Reporting Person is the sole general partner of Vivo Ventures V Affiliates Fund, and may be deemed to beneficially own such securities. The Reporting Person holds voting and dispositive power with respect to the securities held by Vivo Ventures V Affiliates Fund. Edgar Engleman, Albert Cha and Frank Kung are members of the Reporting Person and disclaim beneficial ownership of the securities held by Vivo Ventures V Affiliates Fund, except to the extent of any pecuniary interest therein.
The warrant has a term of three years and, in the event of positive Phase III results for Diazoxide Choline Controlled-Release (DCCR) tablet in Prader-Willi syndrome (PWS), the warrant will expire 30 days from the announcement of such results.
The reported securities are included within 1,072,888 units purchased by the Reporting Person for $1.8425 per unit. Each unit consists of one share of common stock and one warrant to acquire 74% of a share of common stock.
The reported securities are included within 12,592 units purchased by the Reporting Person for $1.8425 per unit. Each unit consists of one share of common stock and one warrant to acquire 74% of a share of common stock.
/s/ Frank Kung, Managing Member
2017-12-19